Delhi, Jan 13, 2017: The Supreme Court on Friday sought the government’s response on a plea regarding the tuberculosis medicines. The government ha said that the existing stocks of tuberculosis medicine can be utilized for giving daily doses to patients.
Chief Justice Jagdish Singh Khehar and Justice D.Y. Chandrachd sought the government’s response as PIL petitioner Raman Kakkar said that the government could well use its existing stocks for giving daily doses of tuberculosis medicine to the patients.
Go to NewsGram and check out news related to political current
Kakkar, a Haryana-based medical officer associated with revised national TB control programme of India, is seeking the implementation of the government decision to administer TB doses to patients every day instead of the earlier practice of thrice a week.
He pointed out that TB medicines stocked with the government could be utilized for the present and arrangement for the future could be made in due course.
The court on Friday asked the Deputy Director General (TB) in the Health and Family Welfare Ministry to file an affidavit stating the government position on the plea.
In December 2016, the central government told the top court that it had decided to phase out the intermittent doses regime and switch over to daily doses.
The court was told that the switch-over would commence in five states.
Kakkar moved the top court for shifting to daily doses regime after studying 5,300 cases where he found the reappearance of the disease in patients who were treated and cured by giving doses thrice a week.
He found that in many cases, the resurfacing of the disease proved to be fatal. (IANS)
When Moustapha Dieng came down with stomach pains one day last month he did the sensible thing and went to a doctor in his hometown of Ouagadougou, Burkina Faso’s capital, Africa.
The doctor prescribed a malaria treatment but the medicine cost too much for Dieng, a 30-year-old tailor, so he went to an unlicensed street vendor for pills on the cheap.
“It was too expensive at the pharmacy. I was forced to buy street drugs as they are less expensive,” he said. Within days he was hospitalized — sickened by the very drugs that were supposed to cure him.
Tens of thousands of people in Africa die each year because of fake and counterfeit medication, an E.U.-funded report released on Tuesday said. The drugs are mainly made in China but also in India, Paraguay, Pakistan and the United Kingdom.
Almost half the fake and low-quality medicines reported to the World Health Organization (WHO) between 2013 and 2017 were found to be in sub-Saharan Africa, said the report, also backed by Interpol and the Institute for Security Studies.
“Counterfeiters prey on poorer countries more than their richer counterparts, with up to 30 times greater penetration of fakes in the supply chain,” said the report.
Substandard or fake anti-malarials cause the deaths of between 64,000 and 158,000 people per year in sub-Saharan Africa, the report said.
The counterfeit drug market is worth around $200 billion worldwide annually, WHO says, making it the most lucrative trade of illegally copied goods. Its impact has been devastating.
Nigeria said more than 80 children were killed in 2009 by a teething syrup tainted with a chemical normally used in engine coolant and blamed for causing kidney failure.
For Dieng, the cost can be measured in more than simple suffering. The night in hospital cost him more than double what he would have paid had he bought the drugs the doctor ordered.
“After taking those drugs, the provenance of which we don’t know, he came back with new symptoms … All this had aggravated his condition,” said nurse Jules Raesse, who treated Dieng when he stayed at the clinic last month.
Fake drugs also threaten a thriving pharmaceutical sector in several African countries.
That has helped prompt Ivory Coast – where fake drugs were also sold openly – to crack down on the trade, estimated at $30 billion by Reuters last year.
Ivorian authorities said last month they had seized almost 400 tonnes of fake medicine over the past two years.
Able Ekissi, an inspector at the health ministry, told Reuters the seized goods, had they been sold to consumers, would have represented a loss to the legitimate pharmaceutical industry of more than $170 million.
“They are reputed to be cheaper, but at best they are ineffective and at worst toxic,” Abderrahmane Chakibi, Managing Director of French pharmaceutical firm Sanofi’s sub-Saharan Africa branch.